Harper Meds review

The public entry now identifies both drugs and a plan condition

Harper Meds' current public intake entry displays semaglutide at $149 per month and tirzepatide at $196 per month, with a three-month-plan condition beside the tirzepatide amount. Its homepage describes a program from $149 monthly and includes doctor consultation, prescription, medication and shipping without extra fees. The named-drug banner is visible before answering the first question. It establishes advertised amounts, not a complete prescribed-dose order or a flexible monthly alternative. Confirm whether the three-month condition also governs the semaglutide offer and obtain the total obligation before paying.

The homepage FAQ describes automatic monthly billing and shipping, notice before a shipment, and cancellation anytime without a long-term contract. The three-month condition in the intake banner needs to be reconciled with that description for the actual selected plan. Ask what is charged initially, when the next payment occurs and what remains payable if you stop during the advertised term. A monthly-looking amount does not establish that you can buy one month independently or recover the unused part of a longer purchase.

The FDA letter is tied to the actual company

The FDA issued warning letter 728281, to Nexus Health Solutions LLC, doing business as Harper Meds. The source connects the company with Harper’s domain and Jersey City address. That is a specific identity match, not a warning attributed through a person or company with a similar name.

The letter concerns false and misleading claims and misbranding. Those dated findings are material context when evaluating the offer, but they do not establish what an individual patient will experience or prove that every later prescription was separately assessed by the FDA. Read the actual scope of the finding alongside the seller’s current product explanation.

Different pages have carried conflicting approval language

A secondary Harper advertorial still quoted semaglutide at $299 monthly with $75 off the first purchase during the October 14 recheck. It also retained obsolete language about approved compounded medication and shortage availability. That page does not resolve the current billing contract or justify replacing a separate homepage amount. Compounded medications are not FDA-approved products; obtain the actual current prescription and payment agreement.

Compounded finished medications are not FDA-approved, and a facility-related claim does not change that distinction. Ask the clinician and dispensing pharmacy to identify the actual product, ingredients, concentration, quantity, storage and instructions. A familiar active ingredient or an approval-sounding heading should not substitute for the regulatory status of the formulation actually being supplied.

The clinical organizations are named, but access remains unclear

Harper identifies Wasef Health and Beluga Health as clinical networks and describes itself as a facilitator. Its legal information names Nexus Health Solutions LLC and a Jersey City address. Those disclosures help distinguish the consumer business from the professionals making treatment decisions, while the actual assigned clinician still needs to be identified.

No state list or broad confirmed service footprint is published in its public information. Ask whether the clinical service and pharmacy can serve the intended location before relying on a price. Someone seeking an independent second opinion should also investigate the actual treating network rather than assuming a different storefront name means an entirely different clinical team.

Current supply duration and maintenance pricing still need a quote

Earlier Harper material explicitly described four weeks of medication. The current monthly banner does not reconfirm that supplied quantity, so the older four-week period should not be attached automatically to today's prices. Nor does the public entry establish a full maintenance-dose ladder or an upfront total for the three-month offer. Request the exact quantity and duration, dose-specific price, prescription-review arrangement and renewal schedule. A price-and-entry check is not a completed intake or evidence that a patient will be approved.

Harper's public information does not establish dedicated postpartum, breastfeeding or PCOS care. Raise relevant needs with the actual clinician rather than relying on a low introductory-looking amount or a brief questionnaire. The current drug-specific offers help identify what to ask about, while the plan commitment, supplied quantity, maintenance charge and dated FDA history remain important. A dependable decision needs a written payment schedule, identified pharmacy and accessible prescriber, with compounded medication's nonapproved status kept distinct from any facility or ingredient claim.